Media Coverage
Analytical Assays Determine Biosimilar Product Quality
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical assays needed to determine and…
Analytical Assays Determine Biosimilar Product Quality
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical assays needed to determine and ensure…
Triangle-based BioAgilytix Acquires Cambridge CRO, Plans Hiring, More Acquisitions
North Carolina Biotechnology Center covers BioAgilytix’s recent acquisition of Cambridge Biomedical in the world’s major biotech center, as well as its plans for future hiring…
Riverside Partners to Score 7.4-Times Return on BioAgilytix
Riverside Partners is set to earn a lofty return from its sale of BioAgilytix Labs LLC, a Durham, N.C.-based provider of molecular bioanalysis services. The…
15 Fastest-Growing Private Life Science Companies in the U.S.
Inc. magazine collates an annual list of the fastest-growing private companies in America. This year, 15 of the top 5,000 were related to healthcare, medical…
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xb3 TM-001 in Brain Cancer
Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program,…
BioAgilytix and ATCC Present the First ‘Trends in Cell-Based Assays’ Forum
The first ‘Trends in Cell-Based Assays’ forum was held this week in Cambridge, hosted by ATCC and BioAgilytix, who partnered with Shire Pharmaceuticals, Takeda Pharmaceuticals,…
Clinical Relevance of Immunogenicity: an Interview with Arno Kromminga
Dr. Arno Kromminga is a certified specialized immunologist with over 20 years of expertise covering the entire cascade of assay strategy and characterization of immune…
Exploratory Biomarker Testing: to Qualify or Validate the Assay?
There is a lot of confusion in the world of biomarker testing when it comes to the terms ‘assay qualification’ and ‘assay validation’. These two…
Immunogenicity Considerations for ADCs: A Focus on Neutralizing Antibody Assays
Summary With increasing numbers of ADCs in clinical trials and post-marketing surveillance, more clinical data are being collected that will increase our understanding of ADCs,…